Are MRI scans safe? Top Hyderabad-based doctor wants you know 6 things before you step in
1. MRI scans are generally safe and radiation-free
2. They're highly accurate
3. But there are three common concerns to note
— hyderabaddoctor (@hyderabaddoctor)
4. If you have metal in your body, consult your doctor
5. Kidney disease? Use contrast dye with caution
6. Pregnant women should weigh risks carefully
In a world where diagnostic technology is advancing rapidly, MRI scans have become a go-to tool for everything from headaches to heart trouble. But just how safe are they, and are there hidden risks patients should be aware of? Dr. Sudhir Kumar , a Hyderabad-based neurologist, took to social media to break it all down in simple terms, offering crucial insights for anyone considering an MRI.Here's what Dr. Kumar wants you to know:MRIs are widely used to diagnose neurological issues related to the brain and spine. They're also effective in identifying problems in the abdomen, heart, and other systems. Unlike CT scans or X-rays, MRI machines do not use radiation. That means no exposure risk during the procedure, one of the biggest advantages of MRI imaging.MRI scans are both sensitive and specific, making them one of the most reliable tools for detecting and diagnosing a wide range of conditions. In many cases, they help doctors catch issues early and with great clarity.Claustrophobia: The enclosed space can trigger anxiety for some patients.Noise: MRI machines are notoriously loud. While earplugs or headphones are usually provided, the sound can still be uncomfortable.Contrast-related allergies: In rare cases, the dye (contrast) used to enhance images may trigger allergic reactions.Anyone with metallic implants, pacemakers, or cochlear devices should get medical clearance before scheduling an MRI. These devices may interfere with the scan or pose safety risks due to the strong magnetic fields.Patients with kidney problems need to be especially careful with contrast dyes. It's essential to consult a nephrologist before undergoing a contrast MRI.MRI scans during pregnancy are not off-limits, but should be done only if the potential benefits outweigh any risks. Contrast dye should be avoided altogether, as it may negatively affect fetal development.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
an hour ago
- Hindustan Times
Former BJP MP's son dies by suicide in Rajasthan's Udaipur
A former MP's son allegedly committed suicide by hanging himself from the ceiling of his room in a library in Rajasthan's Udaipur, police said on Saturday. Ashish Bhagora, the son of former BJP MP from Salumbar Mahaveer Bhagora, was a library operator in Amba Mata area and was living in a room of the library for some time. On Saturday morning, he was found dead in his room. The body was lying on the ground and a piece of cloth was hanging from the ceiling. "Prima facie, he hanged himself from the ceiling last night and the body later fell on the ground. The body was shifted to the mortuary of the government hospital for postmortem," police said. His father Mahaveer Bhagora died due to corona infection in 2021. The matter came to light when some students reached the library and called him. When there was no response, they somehow entered the room and found him dead. The matter is being investigated to ascertain the causes of the suicide, the police said. Discussing suicides can be triggering for some. However, suicides are preventable. A few major suicide prevention helpline numbers in India are 011-23389090 from Sumaitri (Delhi-based) and 044-24640050 from Sneha Foundation (Chennai-based).
Hindustan Times
2 hours ago
- Hindustan Times
IMA urges Tata Sons to support injured medical students after Air India 171 crash
The Indian Medical Association of the Gujarat State Branch on Friday wrote a letter to the Chairman of Tata Sons, requesting to extend support for injured and deceased medical students following the plane crash at the premises of the BJ Medical College in Ahmedabad. In a letter to N Chandrasekaran, Chairman of Tata Sons, the IMC said, "On behalf of the Indian Medical Association - Gujarat State Branch, we extend our heartfelt appreciation for Air India's announcement of ₹1 crore compensation to the families of the passengers who tragically lost their lives in the recent incident, and for your generous support towards the renovation of the BJMC college hostel." "We humbly request you also to consider extending financial assistance and necessary support to the medical students present at the crash site who were injured or lost their lives in this unfortunate event," said the letter. "These individuals were not only victims but also future pillars of our healthcare system, and their well-being and families deserve similar care and support. Accordingly, we earnestly request you to declare immediately similar help to the medical students injured or who have lost their lives. We sincerely hope you will consider this request with compassion and urgency," the letter stated. Meanwhile, officials from the Aircraft Accident Investigation Bureau (AAIB) arrived in Ahmedabad, where the London-bound Air India flight crashed on June 12, killing 241 people out of 242 onboard. The AAIB, a division under the Ministry of Civil Aviation, is responsible for probing aircraft accidents in India. On Thursday, Union Civil Aviation Minister Ram Mohan Naidu confirmed that a formal investigation has been launched into the crash of Air India flight AI-171. The Boeing 787-8, Air India flight 171 from Ahmedabad to London, crashed into a resident doctors' hostel building shortly after taking off from Sardar Vallabhbhai Patel International Airport. The US-based National Transportation Safety Board (NTSB) is preparing to send a team of investigators to India to assist in the ongoing probe into the deadly crash. In parallel, the Indian government has constituted a high-level multidisciplinary committee to examine the causes leading to the crash and recommend preventive measures. "The Committee will examine the existing Standard Operating Procedures (SOPs) and guidelines issued to prevent and handle such occurrences and suggest comprehensive guidelines for dealing with such instances in the future," stated an order issued by the Ministry of Civil Aviation. "The Committee will not be a substitute for other enquiries being conducted by relevant organisations but will focus on formulating SOPs for preventing and handling such occurrences in the future," the order clarified. According to the ministry, the committee will have access to all relevant records, including flight data, cockpit voice recordings, aircraft maintenance logs, air traffic control records, and witness testimonies. The panel is expected to submit its report within three months. The committee is chaired by the Union Home Secretary and includes representatives from the Ministry of Civil Aviation, the Indian Air Force, and aviation experts. It also noted that it will formulate a comprehensive SOP and suggest the roles of all agencies and organisations of the central and state governments to deal with post-crash incident handling and management.
Hindustan Times
3 hours ago
- Hindustan Times
Health Talk: Bharat Biotech-GSK's Shigella vaccine candidate holds promise
Hyderabad-based Bharat Biotech has partnered with GSK—a British multinational pharmaceutical and biotechnology company—for the ongoing development and potential use of the Shigella vaccine candidate, altSonflex1-2-3, the companies announced in a joint statement on Thursday. The partnership will mark a critical step in the advancement of this promising vaccine, targeting Shigellosis—a severe form of bacterial diarrhoea that disproportionately affects children under five in low- and middle-income countries. India is also impacted. A 2021 study published in the Indian Journal of Medical Biology— Antimicrobial Resistant Shigella in North India Since the Turn of the 21st Century — talks about how the ubiquitous presence and rampant spread of Shigellosis in Asian and African countries, along with the emergence of antibiotic-resistant strains, is particularly concerning. 'The scientific community must focus efforts to identify the drugs most suitable for empirical therapy according to these antibiograms. To decrease the morbidity and mortality associated with diarrhea in our country, we not only need newer antimicrobials, cost-effective vaccines but also public health measures such as safe drinking water and sanitation…,' concluded researchers in the paper. Talking about the partnership, Bharat Biotech executive chairman Krishna Ella said, 'As the market leader in vaccines for diarrhoeal infections, including rotavirus, typhoid, polio, non-typhoidal salmonella, cholera, and paratyphi, Bharat Biotech is proud to partner with GSK to develop a next-generation Shigella vaccine candidate, for a severe form of bacterial diarrhoea affecting millions of children under five.' 'With no approved vaccine currently available and antimicrobial resistance on the rise, there is an urgent need for scalable, science-backed solutions focused on low- and middle-income countries. This collaboration combines our strengths in innovation, manufacturing, and global health commitment. The use of Generalised Modules for Membrane Antigens (GMMA) technology reflects our mission to deliver accessible vaccines that protect and improve lives worldwide,' Ella added. According to the statement issued, altSonflex1-2-3 has already shown encouraging results in early-stage clinical trials. 'A Phase 1 study conducted in Europe demonstrated a favourable safety profile and strong immune response. Subsequent Phase 2 trials in Africa, including vaccination of 9-month-old infants—the primary target population—reported no safety concerns. Interim results from 2024 confirmed that the candidate met its pre-set immunogenicity goals,' it read. The vaccine candidate represents one of the most advanced Shigella vaccine candidates globally. With no licensed Shigella vaccine currently available and rising antimicrobial resistance, this candidate stands out for its broad serotype coverage, innovative GMMA-based platform, and robust early clinical results. GMMA technology is an innovative platform that uses bacterial outer membranes to deliver the O Antigen to the immune system. This approach allows for high-yield production with a simple and cost-effective manufacturing process, offering a pathway to create affordable vaccines for underserved populations. As part of this agreement, Bharat Biotech will lead the further development of the vaccine candidate, including Phase 3 clinical trials, regulatory advancement, and large-scale manufacturing. GSK will continue to support the programme by assisting with clinical trial design, securing external funding, and contributing to the access and delivery plans and commercialisation strategy. 'With young children in lower-income countries disproportionately impacted by Shigella, the development of a low-cost vaccine is an important goal for global public health. With no licensed vaccines widely available, the development of our Shigella vaccine candidate, which has demonstrated promising clinical trial results, fills us with immense pride,' GSK chief global health officer Thomas Breuer said. Having effective vaccines, which are also cost-effective, can reduce the overall disease burden significantly.
